Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Destini Gibbs, Herman Van Besien, BA, Stephenson Regan, Ankur Singh, PhD, Matthew Teater, Ethel Cesarman, MD PhD, Ari Melnick, MD, Lisa Giulino Roth, MD

Blood (2019) 134 (Supplement_1): 304.

https://doi.org/10.1182/blood-2019-126790

Published: 2019

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD

Blood (2016) 128 (22): 3502.

https://doi.org/10.1182/blood.V128.22.3502.3502

Published: 2016

Journal Articles

Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children's Oncology Group Study AHOD0031

Lisa Giulino-Roth, MD, Qinglin Pei, PhD, Allen Buxton, MS, Suzanne Wolden, MD, Louis S. Constine, MD, Kara M. Kelly, MD, Cindy L. Schwartz, MD MPH, Debra L. Friedman, MD MS

Blood (2016) 128 (22): 924.

https://doi.org/10.1182/blood.V128.22.924.924

Published: 2016

Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD

Blood (2016) 128 (22): 4203.

https://doi.org/10.1182/blood.V128.22.4203.4203

Published: 2016

Journal Articles

Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma

Lisa Giulino Roth, MD, Herman van Besien, Anna Rodina, PhD, Tony Taldone, PhD, Hediye Erdjument-Bromage, PhD, Matthew J. Barth, MD, Gabriela Chiosis, PhD, Ethel Cesarman

Blood (2015) 126 (23): 592.

https://doi.org/10.1182/blood.V126.23.592.592

Published: 2015

Journal Articles

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

Lisa Giulino Roth, MD, Tara O'Donohue MD, Tanya Trippett, MD, Elizabeth Klein, MPH, Nancy A. Kernan, MD, Rachel Kobos, MD, Susan Prockop, MD, Andromachi Scaradavou, MD, Neerav Shukla, MD, Peter G Steinherz, MD, Alison J Moskowitz, MD, Craig H. Moskowitz, MD, Farid Boulad, MD

Blood (2015) 126 (23): 2000.

https://doi.org/10.1182/blood.V126.23.2000.2000

Published: 2015

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing

Blood (2012) 120 (21): 899.

https://doi.org/10.1182/blood.V120.21.899.899

Published: 2012

NARROW

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children's Oncology Group Study AHOD0031

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma

Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only